ABCSG 18: Monoclonal antibody increases disease-free survival in breast cancer

Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival.

http://www.sciencedaily.com/releases/2015/12/151209105457.htm

Source: ScienceDaily Headlines - December 9, 2015 Category: Science Source Type: news